1 unchanged sentence
Insider Trading Arrangements
−Removed: During the three months ended September 30, 2025 , no director or officer of the Company adopted or terminated a Rule 10b5 - 1 trading arrangement or non-Rule 10b5 - 1 trading arrangement, as each term is defined in Item 408 (a) of Regulation S-K.
+Added: During the three months ended March 31, 2026 , no director or officer of the Company adopted or terminated a Rule 10b5 - 1 trading arrangement or non-Rule 10b5 - 1 trading arrangement, as each term is defined in Item 408 (a) of Regulation S-K.
EXHIBIT INDEX
+Added: Incorporated by Reference Herein
Amended and Restated Certificate of Incorporation of Phio Pharmaceuticals Corp.
+Added: Current Report on Form 8-K (File No.
November 19, 2018
Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Phio Pharmaceuticals Corp.
+Added: Current Report on Form 8-K (File No.
January 14, 2020
Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Phio Pharmaceuticals Corp.
+Added: Current Report on Form 8-K (File No.
January 25, 2023
Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Phio Pharmaceuticals Corp.
+Added: Current Report on Form 8-K (File No.
Certificate of Designation of Series D Preferred Stock, dated November 16, 2022.
+Added: Current Report on Form 8-K (File No.
November 16, 2022
Amended and Restated Bylaws of Phio Pharmaceuticals Corp.
+Added: Current Report on Form 8-K (File No.
Form of Warrant.
+Added: Amendment No.
+Added: 1 to the Registration Statement on Form S-1 (File No.
September 28, 2018
Form of Warrant.
+Added: Current Report on Form 8-K (File No.
April 2, 2020
Form of Common Stock Warrant.
+Added: Current Report on Form 8-K (File No.
January 25, 2021
Form of Placement Agent Warrant
−Removed: February 17, 2021
−Removed: Form of Placement Agent Warrant.
+Added: Current Report on Form 8-K (File No.
December 8, 2023
Form of Series C/D Warrant
+Added: Current Report on Form 8-K (File No.
July 12, 2024
Form of Placement Agent Warrant
+Added: Current Report on Form 8-K (File No.
July 12, 2024
Form of Placement Agent Warrant
+Added: Current Report on Form 8-K (File No.
December 20, 2024
Form of Placement Agent Warrant
+Added: Current Report on Form 8-K (File No.
December 26, 2024
Form of Placement Agent Warrant.
+Added: Current Report on Form 8-K (File No.
January 14, 2024
Form of Placement Agent Warrant.
+Added: Current Report on Form 8-K (File No.
January 15, 2024
Form of Placement Agent Warrant.
+Added: Current Report on Form 8-K (File No.
January 17, 2024
Form of Series J/K Warrant
+Added: Current Report on Form 8-K (File No.
July 30, 2025
Form of Placement Agent Warrant
+Added: Current Report on Form 8-K (File No.
July 30, 2025
Form of Series A Warrant
+Added: Current Report on Form 8-K (File No.
November 6, 2025
Form of Placement Agent Warrant
−Removed: Form of Inducement Letter Agreement dated November 3, 2025, by and between Phio Pharmaceuticals Corp.
−Removed: and the Holders*
−Removed: Separation Agreement and General Release of Claims, dated August 11, 2025, by and between the Company and Robert Infarinato.
−Removed: August 14, 2025
+Added: Current Report on Form 8-K (File No.
+Added: November 13, 2025
+Added: Second Amendment to the Employment Agreement of Robert J.
+Added: Bitterman, dated February 17, 2026, by and between Robert J.
+Added: Bitterman and Phio Pharmaceuticals Corp.#
+Added: Current Report on Form 8-K (File No.
+Added: February 18, 2026
+Added: At the Market Offering Agreement, by and between the Company and H.C.
+Added: Wainwright & Co., LLC, dated April 8, 2026.
+Added: Current Report on Form 8-K (File No.
+Added: April 8, 2026
Sarbanes-Oxley Act Section 302 Certification of Principal Executive Officer.
11 unchanged sentences
Indicates a management contract or compensatory plan or arrangement.
−Removed: Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on November 13, 2025.
+Added: Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on May 7, 2026.
Phio Pharmaceuticals Corp.
2 unchanged sentences
(as Principal Executive Officer)
−Removed: /s/ Lisa Carson
−Removed: Vice President, Finance & Administration
+Added: Chief Financial Officer
(as Principal Financial Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.